There are nearly 70,000 new cancer diagnoses made annually in adolescents and young
adults (AYAs) in the United States. Historically, AYA patients with cancer, aged 15 to 39 …

GLI1 is a transcriptional effector at the terminal end of the Hedgehog signaling (Hh) pathway
and is tightly regulated during embryonic development and tissue patterning/differentiation …

Melanoma is a cancer of melanocytes, with multiple subtypes based on body site location.
Cutaneous melanoma is associated with skin exposed to ultraviolet radiation; uveal …

Simple Summary Adolescents and young adults (AYAs, aged 15–39 years) with cancer form
a distinct patient population within the oncology care setting that is often overlooked in …

PURPOSE The NCI-COG Pediatric MATCH trial assigns patients age 1-21 years with
relapsed or refractory solid tumors, lymphomas, and histiocytic disorders to phase II studies …

The incidence of melanoma, among the most lethal cancers, is widespread and increasing.
Metastatic melanoma has a poor prognosis, representing about 90% of skin cancer …

Background The high mutation rate throughout the entire melanoma genome presents a
major challenge in stratifying true driver events from the background mutations. Numerous …

Cancers cause significant mortality and morbidity in adolescents and young adults (AYAs),
but their biological underpinnings are incompletely understood. Here, we analyze clinical …

Survival of patients with acute myeloid leukemia (AML) is inversely associated with age, but
the impact of race on outcomes of adolescent and young adult (AYA; range, 18-39 years) …

Melanoma is one of the most aggressive tumors of the skin, and its incidence is growing
worldwide. Historically considered a drug resistant disease, since 2011 the therapeutic …